RLIP76 in Human Serum in Adults With Rheumatologic Diseases

Measurement Of RLIP76 Auto Antibodies in Human Serum In Adults With Rheumatologic Diseases.

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00861159

Enrollment

100

Registered

2009-03-13

Start date

2011-09-30

Completion date

2011-09-30

Last updated

2011-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carotid Atherosclerosis

Keywords

RLIP76 Auto Antibodies

Brief summary

It is the investigators aim to determine the feasibility of directly detecting anti-RLIP76 auto-antibodies in human serum using prepared RLIP76 antigen peptides in persons with rheumatologic disease and persons without rheumatologic diesease (healthy subjects).

Detailed description

This is an exploratory study conducted to see the feasibility of measuring the anti-RLIP76 antibody and to standardize the methods for its measurement. We will perform these studies on blood samples obtained from human subjects after informed concent for blood draw for research purposes is obtained by the Clinical Research Co-ordinator (CRC).

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Adult (age 18+), non-pregnant subjects with previously diagnosed rheumatologic disease will be candidates for the study.

Exclusion criteria

* Children, pregnant women, prisoner, persons with any medical condition that precludes phlebotomy, and patients unwilling or unable to provide consent.

Design outcomes

Primary

Measure	Time frame
The focus of the present study is limited to establishing validated protocols for detection of anti-RLIP76 antibodies in human sera.	three years

Countries

United States

Outcome results